Navigation Links
Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Date:9/7/2010

SAN DIEGO, Sept. 7, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:55 a.m. ET / 7:55 a.m. PT in New York, and at the Baird Global Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ET / 8:30 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Morgan Stanley conference. Alex Casdin, vice president, finance of Amylin, will provide a corporate overview at the Baird conference.

The presentations will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and the recordings will be made available on the Web site following the events. To access the live webcasts, please log on to Amylin's Web site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
2. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin and Lilly to Present More than 20 Studies for Exenatide at EASD 2009
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
8. Amylin Pharmaceuticals to Webcast Second Quarter Results
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
11. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):